Tango Therapeutics, Inc. (TNGX)

Market Cap	865.99M
Revenue (ttm)	37.23M
Net Income (ttm)	-111.65M
Shares Out	106.85M
EPS (ttm)	-1.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	791,878
Open	9.00
Previous Close	9.00
Day's Range	8.09 - 9.33
52-Week Range	2.88 - 13.03
Beta	0.79
Analysts	Strong Buy
Price Target	14.17 (+74.83%)
Earnings Date	Aug 5, 2024

About TNGX

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 140
• Stock Exchange: NASDAQ
• Ticker Symbol: TNGX

Financial Performance

In 2023, TNGX's revenue was $36.53 million, an increase of 46.93% compared to the previous year's $24.86 million. Losses were -$101.74 million, -5.95% less than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for TNGX stock is "Strong Buy." The 12-month stock price forecast is $14.17, which is an increase of 74.83% from the latest price.

Price Target

$14.17

(74.83% upside)

Analyst Consensus: Strong Buy